Navigation Links
Painless Hemorrhoid Treatment Adds Management Punch
Date:9/6/2007

ST. PETERSBURG, Fla., Sept. 6 /PRNewswire/ -- Another timely move by Florida-based medical manufacturer, Ultroid Technologies, Inc. (http://www.ultroid.com) has the company adding a former vice president for two important medical distributors to the Ultroid management team.

Don Wilmoth joins Ultroid after more than 20 years in medical sales and distribution upper management. "An emphasis on product/name recognition" is the reason behind acquiring the former Blue Medical vice president, according to Ultroid CEO Michael Cao. As Ultroid's Vice President of Field Operations, Wilmoth is responsible for the acquisition, education and coordination of national/international distributors.

"Ultroid," Cao added, "benefits through Wilmoth's understanding of the distribution side of marketing and the promotion of Ultroid's rising star." His value is obvious to the hemorrhoid treatment manufacturer in his familiarity with distributor needs and the way they perceive the viability of a new product like Ultroid.

"I have been a significant part of what has ultimately become two successful medical distributors in PSS and Blue Medical," Wilmoth said. "What I see in Ultroid," he added, "is a corporation and a product perfectly matched for ultimate growth."

Ultroid Technologies, Inc. produces the painless, Ultroid Hemorrhoid Management System, a non-surgical approach to the painless elimination of hemorrhoids. The FDA-approved product is covered by Medicare and most major insurers.

About Ultroid Technologies, Inc.:

Ultroid Technologies, Inc. (Saint Petersburg, FL) manufactures and markets the Ultroid system for painless TM hemorrhoid treatment. Malpractice insurers report no need for increased premiums because of the procedure's noninvasive nature. The non-surgical technology is a break-through in painless hemorrhoid therapy requiring no anesthesia and no patient-healing down time. Performed in
'/>"/>

SOURCE Ultroid Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. More Women Are Opting For Painless Labor
2. Heart Disease Risk Can Now Be Predicted By A Painless, Non-Invasive Test
3. Painless Control Of Blood Sugar Levels When Detected Early
4. Micro-jets for Painless Needle-free Injections
5. Adding more fiber in the diet can offset hemorrhoids.
6. Hemorrhoid Stapling Has More Long-Term Risks Than Surgical Removal
7. Advances in Treatment of Cataracts
8. Recommendations for Treatment of Blood Pressue
9. Thyroid hormone treatment hastens recovery after cardiac surgery
10. Feeding channel created by malaria parasite - a new target for malaria treatments
11. Now umbilical cord helps in stroke treatment.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... Calif., May 13 /PRNewswire/ -- Personalized medic... pharmacogenomic tests can help,physicians determi...edict,the potential for adverse drug reactions. In...ge protein-based biomarkers to predict drug safety...gulex Inc., a company focused on advancing technol...
(Date:5/13/2008)...es JMR,s BlueStor Storage Array to boost post prod...CHATSWORTH, Calif., May 13 /PRNewswire/ -- JMR Ele...upplier of Storage and Server Platforms,for OEMs, ... its,BlueStor(TM) External PCIe RAID Storage Syste...eyShed ( http://www.honeyshed.com ) as part of the...
(Date:5/13/2008)... of the blood-pressure drugs given in the study we... (HealthDay News) -- Patients who received the blo...after having non-cardiac surgery were at higher ri...dy found. , However, the patients receiving the...ck, according to the report in the May 13 online i...
(Date:5/13/2008)...y 13 /PRNewswire-USNewswire/ -- Donnie Lawless may...uction company promoter, but he,still has a pretty...isabilities - not exactly what you,d expect from a...ith the Hard Rock Cafe at Station Square,Lawless ...ns have planned,Pittsburgh,s first annual Rock for...
Breaking Medicine News(10 mins):Health News:Singulex Advances Conversation on Personalized Medicine 2Health News:JMR Electronics BlueStor(TM) Storage Array Empowers HoneyShed's Post Production Process 2Health News:JMR Electronics BlueStor(TM) Storage Array Empowers HoneyShed's Post Production Process 3Health News:JMR Electronics BlueStor(TM) Storage Array Empowers HoneyShed's Post Production Process 4Health News:Beta Blockers Raise Stroke, Death Risk After Surgery 2Health News:Beta Blockers Raise Stroke, Death Risk After Surgery 3Health News:Rockin' Out for Autism in Pittsburgh 2
... mysterious disease seems to have struck the honey... of them//. At least twenty two states have been a...affected the commercial bee keepers and honey prod...ss of at least half of their bee population. Somet...
...break of bird flu in the southeast of the country ...isease// killed four children in the region. Th...sday 170 chickens had died of bird flu in Bogazkoy...man. The ministry said it believed wild birds had ...
...esian woman is reported to have died due to bird f...un, director general of communicable disease contr...he sixty fourth casualty due to bird flu in this n... any country in the world. According to the heal...
... improve their infrastructure to prevent and manag...vironment Agency is hosting// a World Health Organ...e their ability to tackle the disease. Dengue is...past two to three decades in Southeast Asia and in...
Other Medicine News:Health News:WHO Urges Asian Countries To Improve Infrastructure To Tackle Dengue 2
(Date:5/12/2008)...re-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin B...velopment,company, announced today that it has ent...ement with Fusion Capital Fund II, LLC, a Chicago-...ll up to $10 million of its common stock to Fusion...after the Securities and,Exchange Commission has d...
(Date:5/12/2008)...ination of Scaffolding, Deliverability and ...rael, May 12 /- Medinol is proud to a...llion(TM) CoCr Coronary Stent,enabling physicians...ically,innovative flexible closed cell design sten...ng the unprecedented,balance of flexibility and co...
(Date:5/12/2008)...ewswire-USNewswire/ -- GlaxoSmithKline (GSK),in c...BIG), a leading,academic breast cancer research ne...reast Cancer Cooperative Group (SOLTI), today anno...ill examine the role of TYKERB(R) in the,treatment...patinib and/or,Trastuzumab Treatment Optimization)...
(Date:5/9/2008)...wire-USNewswire/ -- Osteoarthritis is a,painful an...almost 50,million people in the United States. It ...ints. The novel investigational pain medication,ta...ded significant relief,for patients with joint-dis... and with fewer gastrointestinal side effects than...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 1Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm 28iloperidone 29 1445 3Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 1Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 2Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 3Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 4Johnson 26 Johnson Diabetes Institute LLC Launches New Center to Provide State of the Art Education Training to Health Professionals 13105 5Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 1Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 2Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 3Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3626 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 1Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31 2007 3624 17
...007 /PRNewswire/ -- Berlex, Inc., a U.S.,affiliate...oday the,results of a retrospective study demonstr... (NAbs) that can develop in response to,Betaseron(...inical,response in patients with multiple sclerosi...0 patients across three continents. It,is the larg...
...SINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics In...S.,Phase 2 study of Proellex(TM), an oral drug bei...ds. This study suggests that,treatment with Proell...mprovement in symptoms associated with uterine,fib...ils and Results , This 12 week, double-blind study...
Other Medicine Technology:Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 2Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 3Large Study Shows that Presence of Neutralizing Antibodies Did Not,Predict Clinical Response to Betaseron Treatment 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases.
Passive heat and moisture exchangers for respiratory applications.
Medicine Products: